drugset
drugset / Trial / NCT02760758

A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects

NCT02760758 ↗

Phase 1 Completed 76 enrolled Cocrystal Pharma, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a First in Human study of orally administered CDI-31244, a non-nucleoside inhibitor (NNI) in healthy volunteers and HCV infected individuals

Timeline

Start
2016-04
Primary completion
2017-03
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CDI-31244 Unknown 20 mg Oral
Subject CDI-31244 Unknown 50 mg Oral
Subject CDI-31244 Unknown 100 mg Oral
Subject CDI-31244 Unknown 200 mg Oral
Subject CDI-31244 Unknown 400 mg Oral
Subject CDI-31244 Unknown 600 mg Oral
Subject CDI-31244 Unknown 800 mg Oral

Indications

hepatitis C virus infection